

1 **Systemic hypoxemia catalyzes cerebral oxidative-nitrosative stress during extreme apnea in**
2 **humans: implications for cerebral bioenergetic function**

3 Damian M. Bailey^{1*}, Anthony R. Bain^{2*}, Ryan L. Hoiland^{3,4*}, Otto F. Barak^{5,6}, Ivan Drvis⁷,
4 Benjamin S. Stacey¹, Angelo Iannetelli¹, Gareth W. Davison⁸, Rasmus H. Dahl⁹, Ronan M.G.
5 Berg^{1,10}, David B. MacLeod¹¹, Zeljko Dujic^{5*} and Philip N. Ainslie^{1,12*}

6
7 ¹Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of
8 South Wales, Glamorgan, UK; ²Faculty of Human Kinetics, University of Windsor, Windsor,
9 ON, Canada; ³Department of Anaesthesiology, Pharmacology and Therapeutics, Vancouver
10 General Hospital, West 12th Avenue, University of British Columbia, Vancouver, BC, Canada;
11 ⁴Department of Cellular and Physiological Sciences, Faculty of Medicine, University of British
12 Columbia, 2350 Health Sciences Mall, Vancouver, BC, Canada; ⁵School of Medicine, University
13 of Split, Split, Croatia; ⁶Faculty of Medicine, University of Novi Sad, Serbia; ⁷School of
14 Kinesiology, University of Zagreb, Zagreb, Croatia; ⁸Sport and Exercise Science Research
15 Institute, Ulster University Belfast, UK; ⁹Department of Radiology, University Hospital
16 Rigshospitalet, Copenhagen, Denmark; ¹⁰Department of Biomedical Sciences, University of
17 Copenhagen, Denmark; ¹¹Department of Anesthesiology, Duke University Medical Center,
18 Durham, NC, USA and ¹²Center for Heart Lung and Vascular Health, University of British
19 Columbia, Kelowna, British Columbia, Canada

20
21 **Running title:** Redox-regulation of neurovascular complex function

22 **Keywords:** oxygen, carbon dioxide, free radicals, nitric oxide, cerebral bioenergetic function

23
24 *contributed equally

25
26 **Corresponding author**

27 Professor Damian Miles Bailey PhD FRSC FACSM FPVRI FTFS
28 Royal Society Wolfson Research Fellow
29 Director of the Neurovascular Research Laboratory
30 Alfred Russel Wallace Building
31 Faculty of Life Sciences and Education
32 University of South Wales
33 UK CF37 4AT

34
35 Telephone number: +44-1443-482296

36 Fax number: +44-1443-482285

37 email: damian.bailey@southwales.ac.uk

38 Webpage: <http://staff.southwales.ac.uk/users/2240-dbailey1>

39 Twitter: @USW_Oxygen and @DamianMBaileyEP

40 Orcid: <https://orcid.org/0000-0003-0498-7095>

41 **ABSTRACT**

42 **BACKGROUND:** Voluntary asphyxia induced by apnea in competitive breath hold (BH) divers
43 affords a unique opportunity to examine integrated mechanisms underlying the preservation
44 of cerebral bioenergetic function. This study examined to what extent physiological extremes
45 of oxygen (O₂) demand and carbon dioxide (CO₂) production impact redox homeostasis and
46 corresponding red blood cell (RBC)-mediated cerebral vasodilation.

47 **METHODS:** Ten ultra-elite apneists (6 men, 4 women) aged 33 ± 9 (mean ± SD) years old
48 performed two maximal dry apneas preceded by, [1] normoxic normoventilation resulting in
49 severe hypoxemic hypercapnia apnea (HHA) and [2] hyperoxic hyperventilation designed to
50 prevent hypoxemia resulting in isolated hypercapnic apnea (IHA). Transcerebral exchange
51 kinetics of ascorbate radicals (A[•], electron paramagnetic resonance spectroscopy), lipid
52 hydroperoxides (LOOH, spectrophotometry) and nitric oxide metabolites (NO, tri-iodide
53 reductive chemiluminescence) were calculated as the product of global cerebral blood flow
54 (gCBF, duplex ultrasound) and radial arterial (a) to internal jugular venous (v) concentration
55 gradients determined at eupnea and after apnea.

56 **RESULTS:** Apnea duration increased from 306 ± 62 s during HHA to 959 ± 201 s during IHA (P
57 = <0.001), resulting in individual nadirs of 29 mmHg and 40 % for PaO₂ and SaO₂ respectively
58 in HHA and PaCO₂ peak of 68 mmHg in IHA. Apnea resulted in a more pronounced elevation
59 in the net cerebral output (v>a) of A[•] and LOOH in HHA (P = <0.05 vs. IHA). This coincided
60 with a lower apnea-induced increase in gCBF (P = <0.001 vs. IHA) and related suppression in
61 plasma nitrite (NO₂⁻) uptake (a>v) (P = < 0.05 vs. IHA), implying reduced consumption and
62 delivery of NO consistent with elevated cerebral oxidative-nitrosative stress (OXNOS). While
63 apnea-induced gradients consistently reflected plasma NO₂⁻ consumption (a>v) and RBC iron

64 nitrosylhemoglobin formation ($v > a$), we failed to observe equidirectional gradients consistent
65 with S-nitrosohemoglobin consumption and plasma S-nitrosothiol delivery.

66 **CONCLUSIONS:** These findings highlight a key catalytic role for hypoxemia in cerebral OXNOS

67 with NO_2^- reduction the more likely mechanism underlying endocrine NO vasoregulation with

68 the capacity to transduce physiological O_2 - CO_2 gradients into graded vasodilation.

69 INTRODUCTION

70 The neurovascular complex (NVC) is a recent concept that highlights the functional
71 interaction between the multi-hetero-cellular structure comprising the neurovascular unit
72 (NVU) and the systemic vasculature¹. Precisely how the NVC integrates, coordinates and
73 processes molecular signals that collectively maintain cerebral blood flow (CBF) and
74 structural integrity of the blood–brain barrier (BBB) remains to be fully understood, although
75 emergent evidence suggests a key role for redox-regulation².

76 In support, a neuroprotective hormetic role has emerged for the physiological formation of
77 free radicals and associated reactive oxygen/nitrogen species (ROS/RNS) that enable the
78 sensing and subsequent clearance/delivery of the respiratory gases carbon dioxide (CO₂) and
79 oxygen (O₂) to which the human brain has evolved exquisite sensitivity. In contrast, when
80 excessive and sustained, free radical formation can result in structural destabilization and
81 vascular impairment of the NVU subsequent to oxidative inactivation of vascular nitric oxide
82 (NO), collectively termed oxidative-nitrosative stress (OXNOS)^{3,4}.

83 However, to what extent O₂ and CO₂ tensions independently modulate NVC function
84 including the potentially differential impact on the redox-regulation of nitrite (NO₂⁻) and S-
85 nitrosohemoglobin (SNO-Hb) bioactivity, the principal competing mechanisms underlying
86 endocrine NO vasoregulation⁵, remains to be established. Prolonged apnea performed by
87 ultra-elite breath-hold (BH) divers, given its ability to evoke profound hypoxemic-hypercapnia
88 and compensatory adaptations that preserve bioenergetic homeostasis, affords a unique
89 opportunity to address these knowledge gaps.

90 Extending prior work focused exclusively on BBB integrity⁶, this study combined volumetric
91 assessment of CBF with concurrent sampling of arterio-jugular venous concentration
92 differences ($a-v_D$) to calculate cerebral exchange kinetics of intravascular OXNOS biomarkers

93 in world-class apneists over the course of two maximal, static apneas performed in ambient
94 air. The first was performed following (standard) prior normoxic normoventilation resulting in
95 severe hypoxemia-hypercapnia apnea (HHA) whereas the second followed prior hyperoxic
96 hyperventilation, designed to prevent hypoxemia resulting in isolated hypercapnic apnea
97 (IHA). By manipulating arterial O_2 independent of CO_2 tension, we sought to address the
98 following hypotheses (Figure 1A). First, that cerebral output [venous (v) > arterial (a)] of free
99 radicals and suppression of NO metabolite consumption and CBF would be more pronounced
100 in the normoxic (HHA) compared to hyperoxic (IHA) apnea, implicating hypoxemia as the
101 dominant OXNOS catalyst. Second that the apnea-induced elevation in CBF would be
102 proportional to a net loss ($a > v$) of NO_2^- and SNO-Hb taken to reflect metabolite consumption
103 and delivery of NO.

104 **METHODS**

105 **Ethics**

106 Experimental procedures were approved by the University of Split, Ethics Committee (#H14-
107 00922). All procedures were carried out in accordance with the most (7th) recent amendment
108 of the Declaration of Helsinki of the World Medical Association⁷ (with the exception that it
109 was not registered in a publicly accessible database prior to recruitment) with verbal and
110 written informed consent obtained from all participants.

111

112 **Participants**

113 Ten physically active, elite apneists (6 men, 4 women) aged 33 (mean) \pm 9 (SD) years old with
114 a body mass index of 23 ± 2 kg/m² and forced vital capacity of 6.40 ± 1.48 L volunteered from
115 the Croatian National Apnea Team. At the time of these experiments, six had placed within
116 the world's top 10 within the last 5 years. One female set a new official world record in
117 dynamic apnea while another male set the world record for apnea following prior hyperoxic
118 hyperventilation (24 min 33 s). A medical examination confirmed that all participants were
119 free of cardiovascular, pulmonary and cerebrovascular disease and were not taking any
120 nutritional supplements including over-the-counter antioxidant or anti-inflammatory
121 medications. They were advised to refrain from physical activity, caffeine and alcohol for 24
122 h prior to formal experimentation and maintain their normal dietary behavior. Participants
123 attended the laboratory following a 12 h overnight fast.

124

125 **Design**

126 Parts of this study including blood gas and select aspects of cerebral hemodynamic function
127 (Supplementary material Tables 1-2) have previously been published as part of separate

128 investigations focused on the link between hypercapnia and cerebral oxidative metabolism⁸
129 and hyper-perfusion-mediated structural destabilization of the NVU⁶. Thus, although the
130 present study adopted an identical experimental design, it constitutes an entirely separate
131 investigation complemented by *de novo* experimental measures and *a priori* hypotheses
132 focused exclusively on altered redox homeostasis. Participants were required to perform two
133 maximal apneas preceded by, [1] normoxic normoventilation resulting in severe hypoxemic
134 hypercapnia apnea (HHA) and [2] hyperoxic hyperventilation designed to prevent hypoxemia
135 resulting in isolated hypercapnic apnea (IHA). The order of trials was non-randomized given
136 the long-lasting carryover effects of hyperoxia and fatigue associated with a more prolonged
137 apnea⁸. Data were collected at baseline and timed to coincide with the point of apnea
138 termination (Figure 1B).

139

140 **Procedures**

141 All apneas were completed on a single day with the Croatian national apnea coach present to
142 motivate divers and ensure maximal efforts. Each apnea was preceded by 30 min of supine
143 rest followed by two standardized preparatory (practice) apneas designed to maximize the
144 experimental apneas (see below). The first preparatory apnea was performed at functional
145 residual capacity (FRC) until seven involuntary breathing movements (IBMs) were attained.
146 Two minutes later, the second preparatory apnea was performed at total lung capacity (TLC)
147 lasting for ten IBMs. Participants then rested quietly for 6 min prior to two ‘maximal’ apneas
148 that were each performed at TLC:

149

150

151

152 *Trial 1: Prior normoxic normoventilation- hypoxemic hypercapnia apnea (HHA)*

153 Participants performed a maximal apnea in room air (normoxia).

154

155 *Trial 2: Prior hyperoxic hyperventilation- isolated hypercapnic apnea (IHA)*

156 Participants performed a maximal apnea preceded by 15 min of hyperventilation of 100% O₂

157 while receiving auditory feedback from the coach to achieve an end tidal PCO₂ (PET_{CO2}) of ~20

158 mmHg.

159

160 **Blood sampling**

161 *Catheterization*

162 Participants were placed slightly head down on a hospital bed, and two catheters were

163 inserted retrograde using the Seldinger technique under local anesthesia (1 % lidocaine) via

164 ultrasound guidance. A 20-gauge arterial catheter (Arrow, Markham, ON, Canada) was placed

165 in the right radial artery (a) and attached to an in-line waste-less sampling setup (Edwards

166 Lifesciences VAMP, CA, USA) connected to a pressure transducer that was placed at the

167 height of the right atrium (TruWave transducer). A central venous catheter (Edwards

168 PediaSat Oximetry Catheter, CA, USA) was placed in the right internal jugular vein (v) and

169 advanced towards the jugular bulb located at the mastoid process, approximately at the C1-

170 C2 interspace (Figure 1). Facial vein contamination was ruled out by ensuring that all jugular

171 venous oxyhemoglobin saturation (SO₂) values were < 75% at rest. Participants rested for at

172 least 30 min following catheter placement prior to the collection of baseline samples.

173

174

175

176 ***Collection and storage***

177 Blood samples were drawn without stasis simultaneously from the RA and JV directly into
178 Vacutainers (Becton, Dickinson and Company, Oxford, UK) before centrifugation at 600g (4°C)
179 for 10 min. With the exception of blood for determination of blood gas variables, plasma and
180 red blood cell (RBC) samples were decanted into cryogenic vials (Nalgene Labware, Thermo
181 Fisher Scientific Inc, Waltham, MA) and immediately snap-frozen in liquid nitrogen (N₂)
182 before transport under nitrogen gas (Cryopak, Taylor-Wharton, Theodore, AL) from Croatia
183 to the United Kingdom. Samples were left to defrost at 37°C in the dark for 5 minutes prior to
184 batch analysis.

185

186 **Measurements**

187 ***Blood gases***

188 Whole blood was collected into heparinized syringes, maintained anaerobically at room
189 temperature and immediately analyzed for hemoglobin (Hb), hematocrit (Hct), partial
190 pressures of oxygen, carbon dioxide (PO₂/PCO₂), SO₂, pH and glucose (Glu) using a
191 commercially available cassette-based analyzer (ABL-90 FLEX, Radiometer, Copenhagen,
192 Denmark). Hydrogen ion (H⁺) concentration was calculated as $[H^+] = 10^{-pH}$. The intra- and
193 inter-assay CVs for all metabolites were both <5%⁹.

194

195 ***Antioxidants***

196 Plasma was stabilized and deproteinated using 10% metaphosphoric acid (Sigma Chemical,
197 Dorset, UK). Ascorbic acid was assayed by fluorimetry based on the condensation of
198 dehydroascorbic acid with 1,2-phenylenediamine¹⁰. Concentrations of the lipid soluble
199 antioxidants (LSA) encompassing α/γ -tocopherol, α/β -carotene, retinol and lycopene were

200 determined using high-performance liquid chromatography (HPLC)^{11, 12}. The intra- and inter-
201 assay CVs for both metabolites were both <5%⁹.

202 *Free radicals*

203 *Ascorbate free radical (A⁻)*: We employed electron paramagnetic resonance (EPR)
204 spectroscopic detection of A⁻ as a direct measure of global systemic free radical formation⁹.
205 Plasma (1 mL) was injected directly into a high-sensitivity multiple-bore sample cell (AquaX,
206 Bruker Daltonics Inc., Billerica, MA, USA) housed within a TM₁₁₀ cavity of an EPR
207 spectrometer operating at X-band frequency (9.87 GHz). Samples were recorded by
208 cumulative signal averaging of 10 scans using the following instrument parameters:
209 resolution, 1024 points; microwave power, 20 mW; modulation amplitude, 0.65 G; receiver
210 gain, 2×10^6 ; time constant, 40.96 ms; sweep rate, 0.14 G/s; sweep width, 6 G; centre field,
211 3486 G. All spectra were filtered identically (moving average, 15 conversion points) using
212 WINEPR software (Version 2.11, Bruker, Karlsruhe, Germany) and the double integral of each
213 doublet quantified using Origin 8 software (OriginLab Corps, MA, USA). The intra- and inter-
214 assay CVs were both <5%⁹.

215

216 *Lipid hydroperoxides (LOOH)*: LOOH were determined spectrophotometrically via the ferric
217 oxidation of xylenol orange (FOX) version II method, with modification⁹. Intra- and inter-assay
218 CVs were <2 % and <4 % respectively⁹.

219

220 *Nitric oxide (NO) metabolites*

221 Ozone-based chemiluminescence (Sievers NOA 280i, Analytix Ltd, Durham, UK) was used to
222 detect NO liberated from plasma and RBC samples via chemical reagent cleavage facilitating
223 detection of plasma and red blood cell (RBC) NO₂⁻, S-nitrosothiols (RSNO), S-

224 nitrosohemoglobin (SNO-Hb) and iron nitrosylhemoglobin (HbNO) according to established
225 methods¹³⁻¹⁵. Total NO bioactivity was calculated as the cumulative concentration of plasma
226 and RBC metabolites. Signal output was plotted against time using Origin 8 software
227 (OriginLab Corps, Massachusetts, USA) and smoothed using a 150-point averaging algorithm.
228 The Peak Analysis package was used to calculate the area under the curve and subsequently
229 converted to a concentration using standard curves of sodium NO₂⁻. Intra- and inter-assay CVs
230 for all metabolites were both <10%¹³.

231

232 *Cardiopulmonary function*

233 All cardiopulmonary measurements were averaged over 15 s immediately prior to blood
234 sampling. A lead II electrocardiogram (Dual BioAmp; ADInstruments, Oxford, UK) was used to
235 measure heart rate (HR). Intra-arterial ABP was recorded directly via a pressure transducer
236 placed at the level of the heart for determination of mean arterial pressure (MAP). Internal
237 jugular venous pressure (IJVP) was measured with the transducer connected to the jugular
238 catheter. End-tidal partial pressures of oxygen and carbon dioxide (PET_{O₂/CO₂}) were measured
239 via capnography (ML 206, ADInstruments Ltd, Oxford, UK). Finger photoplethysmography
240 (Finometer PRO, Finapres Medical Systems, Amsterdam, The Netherlands) was used to
241 measure beat-by-beat stroke volume (SV) and cardiac output (\dot{Q}) using the Modelflow
242 algorithm¹⁶ that incorporates participant sex, age, stature and mass (BeatScope 1.0 software;
243 TNO; TPD Biomedical Instrumentation, Amsterdam, The Netherlands).

244

245 *Cerebrovascular function*

246 *Intracranial:* Blood velocity in the middle cerebral artery (MCAv, insonated through the left
247 temporal window and posterior cerebral artery (PCAv, insonated at the P1 segment through

248 the right temporal window) were measured using standardized procedures with a 2 MHz
249 pulsed transcranial Doppler ultrasound (TCD; Spencer Technologies, Seattle, WA, USA).
250 Bilateral TCD probes were secured using a specialized commercial headband (Mark600,
251 Spencer Technologies, Seattle, WA, USA) using standardized search techniques.

252

253 *Extracranial:* Continuous diameter, velocity and blood flow recordings in the right internal
254 carotid and left vertebral arteries ($\dot{Q}_{ICA}/\dot{Q}_{VA}$) were obtained using a 10 MHz, multifrequency,
255 linear array vascular ultrasound (Terason 3200, Teratech, Burlington, MA). Arterial diameter
256 was measured via B-mode imaging, whereas peak blood velocity was simultaneously
257 measured with pulse-wave mode. The ICA was insonated ≥ 1.5 cm from the carotid
258 bifurcation, with no evidence of turbulent or retrograde flow present during recording. The
259 VA was insonated at the C4–C5 or C5–C6 vertebral segment and standardized within
260 participants for the HHA and IHA trials. The steering angle was fixed to 60° and the sample
261 volume was placed in the center of the vessel and adjusted to cover the entire vascular
262 lumen. All images were recorded as video files at 30 Hz and stored for offline analysis using
263 customized edge detection software designed to mitigate observer bias¹⁷. Simultaneous
264 measures of arterial diameter and velocity over >12 consecutive cardiac cycles were used to
265 calculate flow. Between-day CVs for \dot{Q}_{ICA} and \dot{Q}_{VA} are 5 % and 11 %, respectively¹⁸.

266

267 **Data integration**

268 All cardiopulmonary measurements were sampled at 1 kHz and integrated into PowerLab®
269 and LabChart® software (ADInstruments, Bella Vista, NSW, Australia) for online monitoring
270 and saved for offline analysis.

271

272

273 Calculations

274 *Cerebral bioenergetics*

275 *Perfusion:* Volumetric blood flow was calculated offline as:

$$276 \quad \dot{Q}_{ICA} \text{ or } \dot{Q}_{VA} \text{ (mL/min)} = \frac{\text{peak envelope blood velocity}}{2} \times [\pi(0.5 \times \text{diameter})^2] \times 60$$

277 \dot{Q}_{ICA} or \dot{Q}_{VA} were averaged for a 1 min eupnea baseline and during the last 30 s of apnea.

278

279 During the latter half of each apnea, IBMs and corresponding contraction of the

280 sternocleidomastoid prevented reliable blood velocity traces. To circumvent this, Q_{ICA} and

281 Q_{VA} were estimated (e) from changes in MCAv (for \dot{Q}_{ICA}) and PCAv (for \dot{Q}_{VA}) respectively, as

282 previously described^{19, 20}:

283

$$284 \quad \text{Apnea eICAv and eVAv} = \text{Eupnea ICAv and VA v} \times \left(\frac{\text{Apnea MCAv or PCAv}}{\text{Eupnea MCAv or PCAv}} \right)$$

$$285 \quad \dot{Q}_{ICA} \text{ or } \dot{Q}_{VA} \text{ (mL/min)} = \text{eICAv or eVAv} \times \pi \left(\frac{\text{diameter}}{2} \right)^2$$

286

287 Assuming symmetrical blood flow of contralateral ICA and VA arteries, global cerebral blood

288 flow (gCBF) was calculated as:

289

$$290 \quad \text{gCBF (mL/min)} = 2 \times (\dot{Q}_{ICA} + \dot{Q}_{VA})$$

291

292 Cerebral perfusion pressure (CPP) was calculated as MAP-IJVP with the latter serving as a

293 surrogate for ICP²¹.

294

295 *Metabolism:* Arterial and jugular venous oxygen content (caO_2 and cvO_2 respectively) were
296 calculated as:

$$297 \quad caO_2 \text{ (mL/dL)} = \text{Hb (g/dL)} \times 1.34 \left(\frac{SaO_2 (\%)}{100} \right) + 0.003 \times PaO_2$$

$$298 \quad cvO_2 \text{ (mL/dL)} = \text{Hb (g/dL)} \times 1.34 \left(\frac{SvO_2 (\%)}{100} \right) + 0.003 \times PvO_2$$

299

300 where 1.34 is the O_2 binding capacity of Hb and 0.003 is the solubility of O_2 dissolved in
301 blood.

302

303 Global cerebral O_2 and glucose delivery ($gCDO_2/gCD_{\text{Glucose}}$) were calculated as:

$$304 \quad gCDO_2 \text{ (mL/min)} = \left(\frac{gCBF \text{ (mL/min)}}{100} \right) \times caO_2 \text{ (mL/dL)}$$

305

$$306 \quad gCD_{\text{Glu}} \text{ (mmol/min)} = \left(\frac{gCBF \text{ (mL/min)}}{1000} \right) \times a_{\text{Glucose}} \text{ (mmol/L)}$$

307

308 The cerebral metabolic rate of oxygen ($CMRO_2$) and glucose (CMR_{Glucose}) were calculated as:

$$309 \quad CMRO_2 \text{ (mL/min)} = \left(\frac{gCBF \text{ (mL/min)}}{100} \right) \times caO_2 - cvO_2 \text{ (mL/dL)}$$

310

$$311 \quad CMR_{\text{Glucose}} \text{ (mmol/min)} = \left(\frac{gCBF \text{ (mL/min)}}{1000} \right) \times a_{\text{Glucose}} - v_{\text{Glucose}} \text{ (mmol/L)}$$

312

313 *Transcerebral exchange kinetics*

314 $gCBF$ was converted into global cerebral plasma ($gCPF$) and red blood cell ($gCRBCF$) flow:

315

$$316 \quad gCPF \text{ (mL/min)} = gCBF \left(1 - \frac{Hct_a}{100} \right)$$

317

318
$$\text{gCRBCF (mL//min)} = \text{gCBF} \left(\frac{\text{Hct}_a}{100} \right)$$

319 for corresponding calculation of net transcerebral exchange kinetics of plasma/serum/RBC-

320 borne metabolites according to the Fick principle:

321

322
$$\text{Exchange } (\mu\text{mol or nmol/min}) = \text{gCBF or gCPF or gCRBCF} \times (a - v_D).$$

323 By convention, a positive value ($a > v$) refers to net uptake (loss or consumption) whereas a

324 negative value ($v > a$) indicates net output (gain or formation) across the cerebrovascular bed.

325

326 **Data analysis**

327 Data were analyzed using the Statistics Package for Social Scientists (IBM SPSS Statistics

328 Version 29.0). Distribution normality was confirmed using Shapiro-Wilk W tests ($P > 0.05$).

329 Data were analyzed using a combination of two (*State*: Eupnea vs. Apnea \times *Site*: Arterial vs.

330 Venous) and three (*Trial*: HHA vs. IHA \times *State*: Eupnea vs. Apnea \times *Site*: Arterial vs. Venous)

331 factor repeated measures analyzes of variance. Post-hoc Bonferroni-corrected paired

332 samples t -tests were employed to locate differences following an interaction. Relationships

333 between selected variables were analyzed using Pearson Product Moment Correlations.

334 Significance was established at $P < 0.05$ for all two-tailed tests and data presented as mean \pm

335 SD.

336

337 **RESULTS**

338 **Apnea**

339 Apnea duration increased from 306 ± 62 s (range: 217-409 s) during HHA to 959 ± 201 s
340 (range: 579-1262 s) during IHA ($P = <0.001$).

341

342 **Blood gas variables**

343 As expected, apnea induced severe systemic and local hypoxemia ($\downarrow PO_2$, $\downarrow SO_2$, $\downarrow cO_2$),
344 hypercapnia ($\uparrow PCO_2$) and acidosis ($\downarrow pH$, $\uparrow HCO_3^-$) in NX (Supplemental Table 1). In one
345 participant, nadirs of 29 mmHg and 40 % were recorded for PaO_2 and SaO_2 respectively,
346 corresponding to a (peak) $PaCO_2$ of 53 mmHg in HHA. Participants were hypocapnic at
347 eupnea in IHA and remained hyperoxemic and comparatively less hypertensive and more
348 hypercapnic/acidotic throughout apnea (Supplemental Table 1). The highest individual value
349 recorded for $PaCO_2$ during IHA was 68 mmHg corresponding to a pH of 7.227. Baseline levels
350 of Hb and Hct at eupnea were elevated in IHA (Supplemental Table 1).

351

352 **Cardiopulmonary function**

353 Apnea decreased SV and \dot{Q} in HHA whereas increases were observed in IHA (Table 1). Apnea
354 was associated with a general increase in MAP, IJVP and CPP that were more pronounced in
355 HHA (Supplemental Table 1).

356

357 **Cerebral bioenergetics**

358 Compared to the eupnic control states (normoxic normocapnia), a greater increase in gCBF
359 was observed in IHA ($+206 \pm 52$ %) compared to HHA ($+83 \pm 22$ %, $P = <0.001$) due to
360 consistently lower \dot{Q}_{ICA} and \dot{Q}_{VA} values at baseline subsequent to (hyperoxic)

361 hyperventilation-induced hypocapnia (Supplemental Table 3). Corresponding increases in
362 local (VA/ICA) and global cerebral substrate delivery (O_2 and glucose) were also more
363 pronounced during apnea in IHA (Supplemental Table 3). Apnea generally decreased $CMRO_2$
364 whereas CMR_{Glu} remained preserved with no differences between trials (Supplemental Table
365 3).

366

367 **Oxidative stress**

368 Apnea increased the $a-v_D$ and corresponding net cerebral uptake of ascorbate, α -tocopherol
369 and total LSA that were more pronounced in HHA (Table 1, Figure 2 A-C). This was
370 accompanied by a reduction in the $a-v_D$ and reciprocal elevation in the net cerebral output of
371 $A^{\cdot-}$ and LOOH that were also more marked in HHA for $A^{\cdot-}$ (Table 1, Figure 2 D-E).

372

373 **Nitrosative stress**

374 Figure 3 highlights the dynamic interplay and re-apportionment of NO metabolites across the
375 cerebral circulation observable within the constraints of a single a-v transit. The total NO
376 metabolite pool was generally lower in HHA and during apnea due to a combined reduction
377 in plasma and RBC NO_2^- whereas elevations were observed in SNO-Hb and HbNO (Table 2,
378 Figure 3). Corresponding differences translated into net cerebral uptake of plasma NO_2^- ,
379 RSNO and RBC NO_2^- (Figure 4 A-B, D) that were opposed by net cerebral output of SNO-Hb
380 and HbNO (Figure 4 E-F). Plasma NO_2^- uptake and SNO-Hb/HbNO output were more
381 pronounced during apnea, with plasma NO_2^- uptake generally lower in HHA (Figure 4 A, E-F).
382 The apnea-induced elevation in $A^{\cdot-}$ output was associated with a reduction in plasma NO_2^-
383 uptake in HHA ($r = 0.702$, $P = 0.024$) but not IHA ($r = 0.509$, $P = 0.133$).

384 **DISCUSSION**

385 Local sampling of blood across the cerebral circulation during maximal apnea in world-class
386 BH divers has provided important insight into the mechanisms underlying the redox-
387 regulation of cerebral bioenergetic function during the most severe extremes of O₂
388 demand/CO₂ production recorded to date in unanesthetized and otherwise healthy
389 humans²². Direct measures of intravascular OXNOS and inclusion of the IHA trial designed to
390 prevent hypoxemia and better distinguish between competing vasoactive stimuli, highlights
391 three novel findings. First, the combined elevation in the net cerebral output of A⁻ and LOOH
392 during apnea, collectively taken to reflect increased free radical-mediated lipid peroxidation,
393 was more pronounced in HHA, highlighting a key contribution for hypoxemia. Second, this
394 coincided with a lower apnea-induced elevation in gCBF and related suppression in plasma
395 NO₂⁻ uptake, implying reduced consumption and delivery of NO consistent with increased
396 OXNOS. Finally, that apnea-induced NO₂⁻ uptake and HbNO output prevailed in the face of
397 increased SNO-Hb output and (general) RSNO uptake, tentatively suggests NO₂⁻ reduction as
398 the more likely mechanism underlying endocrine NO vasoregulation with the capacity to
399 transduce physiological O₂-CO₂ gradients into graded vasodilation. Collectively, these findings
400 highlight the dynamic interplay that takes place between free radicals and NO metabolites
401 during a single arteriovenous transit across the cerebral circulation and corresponding
402 implications for cerebral bioenergetic function that may have clinical translational relevance.

403

404 **Hypoxemia is a key stimulus for cerebral OXNOS**

405 We recently documented molecular evidence for structural destabilization of the NVU that
406 was selectively more pronounced during apnea in HHA compared to IHA despite

407 comparatively suppressed, albeit concerted vasodilation⁶. While this was originally attributed
408 purely to the ‘mechanical’ stress imposed by more severe systemic and intracranial
409 hypertension caused by hypoxemia, the present findings suggest a potentially additive role
410 for ‘chemical’ stress, taking the form of elevated OXNOS, to which the human brain is
411 especially vulnerable.

412 To do this, we employed EPR spectroscopic detection of the distinctive A[•] ‘doublet’ as a
413 direct biomarker of global free radical formation with LOOH serving as a distal reactant of
414 lipid peroxidation⁹. That net cerebral uptake (a>v) of ascorbate, α -tocopherol and (total) LSA
415 was observed during apnea in both trials, and more pronounced in HHA, was taken to reflect
416 enhanced sacrificial consumption (uptake by brain parenchyma and/or blood-borne reactions
417 during circulatory transit) to constrain chain initiation-propagation reactions. However, this
418 failed to prevent the overall shift in redox imbalance favouring increased free radical-
419 mediated lipid peroxidation confirmed by proportional increases in the net cerebral output of
420 A[•] and LOOH (v>a) that were selectively elevated in HHA. The greater elevation in A[•] output
421 in HHA exceeded that predicted by prior modelling due to more ascorbate available for
422 oxidation²³ (given increased consumption), highlighting authentic (i.e. *de novo*) free radical
423 formation. Our measured A[•] gradients in HHA (v = 37 % > a) also exceeded those previously
424 recorded during HHA in a separate group of elite apneists²⁴ (v = 4 % > a) and were even more
425 pronounced than those documented during vigorous cycling exercise⁹ (v = 12 % > a) - helping
426 place its magnitude into clearer physiological context.

427 While it is conceivable that hypoxemia, hypercapnia and hyperoxemia independently
428 contributed towards global oxidative stress, it was not experimentally possible to fully
429 differentiate between stimuli, only combinations thereof. Hypoxemia and hyperoxemia
430 independently generate mitochondrial superoxide (O₂^{•-}) and NO[•], notwithstanding

431 contributions from extra-mitochondrial sources including nicotinamide adenine dinucleotide
432 phosphate- and xanthine oxidases, cytochrome P-450 enzymes, lipoxygenases and
433 phagocytes, that can further propagate oxidative stress via secondary formation of hydrogen
434 peroxide (H_2O_2), peroxynitrite (ONOO^-) and Haber-Weiss/Fenton catalyzed hydroxyl radicals
435 (OH^-)^{25, 26}. Furthermore, the addition of (hypercapnic) acidosis, common to both trials yet
436 more severe in HX given the extended BH times, would have been expected to further
437 amplify oxidation since molecular CO_2 can react with ONOO^- and H_2O_2 to form redox reactive
438 carbonate radicals and peroxymonocarbonate²⁷. However, that cerebral oxidative stress was
439 considerably more pronounced in HHA suggests a key catalytic role for hypoxemia that far
440 outweighed the additive effects of hyperoxemia and (more severe) hypercapnia, confirming
441 prior observations in healthy humans albeit exposed to poikilocapnic (hypocapnic) hypoxia⁹,
442 ²⁸.

443 To what extent this represents a physiologically adaptive (molecular signalling) or
444 pathologically maladaptive (structurally damaging) response remains unclear given the
445 pleiotropic mechanisms underlying redox-regulation of NVU function⁴. That oxidative stress
446 was elevated in the face of reduced gCMRO_2 and $\text{gCMR}_{\text{Glucose}}$, attributable in part to
447 hypercapnia⁸, has also been observed in (more) anoxia-hypoxia-tolerant vertebrates and
448 interpreted to reflect an adaptive O_2 -conserving strategy to improve neuronal survival²⁹.

449 However, two observations in the present study tentatively suggest that the overall impact
450 was likely maladaptive. First, that apnea in NX was associated with a lower net uptake of
451 plasma NO_2^- implied reduced consumption of NO, potentially tempering vasodilation (see
452 below). This may reflect oxidative inactivation of NO by $\text{O}_2^{\cdot -}$ and/or secondary lipid-derived
453 alkoxy-alkyl radicals formed subsequent to the reductive decomposition of (elevated) LOOH

454 to form ONOO⁻, collectively taken as evidence for elevated OXNOS ($O_2^{\cdot-}/LO^{\cdot}/LC^{\cdot} + NO \xrightarrow{10^9 M/s}$
455 ONOO⁻)³⁰. Second, that our prior research has shown that apnea induces mild disruption of
456 the BBB and increased neuronal-gliovascular reactivity that were consistently more
457 pronounced in HHA⁶, stands testament to the thermodynamic potential of radicals to cause
458 structural damage to the NVU, which is not unreasonable given its histological vulnerability⁴,
459 ³¹.


460

461 **NO metabolites and vasoregulation**


462 Our findings highlight that the NO metabolite pool is in a perpetual state of dynamic flux
463 even within the time constraints of a single a-v transit and that metabolite re-apportionment
464 between plasma and RBC compartments is not solely related to changes in O₂ but also
465 involves CO₂ and pH (Figure 3). By measuring corresponding gradients of NO₂⁻ and SNO-Hb,
466 the principal metabolites capable of transducing NO bioactivity within the cerebral
467 microcirculation^{32, 33}, we sought to determine if differential changes could further inform the
468 mechanism(s) underlying cerebral vasodilation across extremes of PaO₂ and PaCO₂. Both
469 metabolites likely originated from the combined effects of apnea-induced elevations in
470 shear-mediated conduit vessel endothelial³⁴, neuronal³⁵ NO synthase bioactivation and
471 transpulmonary S-nitrosylation³²; however, their respective roles in endocrine NO signalling
472 and cerebral bioenergetic function remain widely contested, albeit unified by allosteric-
473 coupled Hb deoxygenation and acidic disproportionation⁵.

474 The NO₂⁻ reductase hypothesis favors NO₂⁻ as the major intravascular NO storage molecule
475 with conversion to NO or dinitrogen trioxide (N₂O₃) catalyzed by deoxyHb-mediated
476 reduction and acidic disproportionation^{13, 33, 36}. In contrast, the SNO-Hb hypothesis contends

477 that NO is stabilized, transported, and delivered by intra-molecular NO group transfers
478 between the heme iron and β -93 cysteine, that upon deoxygenation releases an as of yet
479 unidentified moiety that is exported from the RBC involving transnitrosylation of the anion
480 exchanger AE1, as a low molecular weight RSNO to effect vasodilation^{32, 37, 38}.
481 The direction and magnitude of gradients observed are generally more consistent with those
482 predicted by the NO_2^- reductase (as opposed to the SNO-Hb) hypothesis. In support, systemic
483 (a) plasma NO_2^- fell during apnea and was accompanied by a concomitant increase in net
484 uptake implying consumption from artery to vein (a>v), although we cannot discount
485 consistently elevated NO_2^- formation on the arterial side due to elevated NOS activity. Plasma
486 NO_2^- consumption was especially marked in HX, coinciding with the most pronounced
487 elevation in gCBF and where the total NO metabolite pool was greatest. This was
488 accompanied by NO formation with concomitant output (v>a) of HbNO, albeit suppressed in
489 IHA consistent with the prevailing SO_2 since hyperoxemia persisted at end apnea, culminating
490 in an overall net gain in NO metabolites. These findings were taken to reflect a combination
491 of deoxyHb-mediated reduction of NO_2^- in the RBC and acidic disproportionation subsequent
492 to marked hypercapnia-induced acidosis. Local formation of NO, potentially compounded by
493 the observed increase in ascorbate consumption³⁹, binds to vicinal deoxyHb yielding HbNO
494 (Equations 1 and 2) and, to a lesser extent, the intermediate nitrosating species dinitrogen
495 trioxide that can escape the RBC to effect graded vasodilation³³:



497 1)



499

500 The gradients observed reproduce those previously documented across the exercising
501 human forearm circulation and NO_2^- infusion that originally informed the NO_2^- reductase
502 hypothesis^{33, 36}. Similar gradients were more recently documented across the cerebral
503 circulation at rest and in response to acute exercise during hypocapnic hypoxia¹³.
504 In contrast, that apnea stimulated SNO-Hb output ($v>a$) and RSNO uptake ($a>v$) argues
505 against the SNO-Hb hypothesis, since the gradients observed were diametrically opposed to
506 those originally predicted⁴⁰, yet consistent with the observations of other research
507 laboratories^{41, 42}. We would have expected an allosterically mediated release from a-v during
508 circulatory transit, resulting in a drop in the RBC and corresponding rise in plasma RSNO in
509 the venous circulation, consistent with SNO-Hb consumption ($a>v$) and RSNO delivery ($v>a$)
510 during local deoxygenation. Yet, the gradients observed consistently reflected SNO-Hb
511 formation ($v>a$) and RSNO consumption ($a>v$), that in the former, was further compounded
512 during apnea and unrelated to the increase in gCBF.

513

514 **Experimental limitations**

515 Several limitations warrant consideration. First, it was not possible to fully disassociate
516 changes in PaO_2 from PaCO_2 , only combinations thereof, given the inability to ‘match’ end-
517 apnea hypercapnia that was unavoidably more pronounced in HX owing to extended BH
518 times. Second, it was unfortunate that we did not measure plasma 3-nitrotyrosine due to
519 inadequate sample volume: its elevation would have indirectly confirmed increased ONOO^-
520 formation subsequent to oxidative inactivation of NO underlying OXNOS, consistent with our
521 prior observations in hypoxia³⁵. Third, the profiling of NO metabolite gradients, while
522 informative, fails to unequivocally identify the specific NO species responsible for conserving

523 bioactivity and the mechanism(s) underpinning vasoregulation, including potential
524 contributions from ATP-mediated activation of P_{2Y} receptors. Finally, despite prospective
525 power calculations informed by our prior research²⁴, we acknowledge the small sample sizes
526 employed may have limited our ability to detect treatment effects, albeit challenging to
527 perform large-scale invasive studies of this nature. Caveats notwithstanding, mapping the
528 dynamic transvascular interplay of OXINOS biomarkers in this applied model of human
529 asphyxia may prove clinically relevant in that it may help define more sensitive biomarkers of
530 cerebrovascular health and inform interventions designed to optimize tissue oxygenation in
531 the critically ill.

532 REFERENCES

- 533 1. Schaeffer S and Iadecola C. Revisiting the neurovascular unit. *Nat Neurosci.*
534 2021;24:1198-1209.
- 535 2. Rinaldi C, Donato L, Alibrandi S, Scimone C, D'Angelo R and Sidoti A. Oxidative Stress
536 and the Neurovascular Unit. *Life (Basel)*. 2021;11.
- 537 3. Bailey DM. Oxygen, evolution and redox signalling in the human brain; quantum in the
538 quotidian. *The Journal of physiology*. 2019;597:15-28.
- 539 4. Copley JN, Fiorello ML and Bailey DM. 13 reasons why the brain is susceptible to
540 oxidative stress. *Redox biology*. 2018;15:490-503.
- 541 5. Gladwin MT and Schechter AN. NO contest: nitrite versus S-nitroso-hemoglobin.
542 *Circulation Research*. 2004;94:851-5.
- 543 6. Bailey DM, Bain AR, Hoiland RL, Barak OF, Drvis I, Hirtz C, Lehmann S, Marchi N,
544 Janigro D, MacLeod DB, Ainslie PN and Dujic Z. Hypoxemia increases blood-brain barrier
545 permeability during extreme apnea in humans. *Journal of cerebral blood flow and metabolism*
546 : *official journal of the International Society of Cerebral Blood Flow and Metabolism*.
547 2022;42:1120-1135.
- 548 7. WMA. World Medical Association Declaration of Helsinki: ethical principles for
549 medical research involving human subjects. *Journal of the American Medical Association*.
550 2013;310:2191-4.
- 551 8. Bain AR, Ainslie PN, Barak OF, Hoiland RL, Drvis I, Mijacika T, Bailey DM, Santoro A,
552 DeMasi DK, Dujic Z and MacLeod DB. Hypercapnia is essential to reduce the cerebral
553 oxidative metabolism during extreme apnea in humans. *Journal of Cerebral Blood Flow and*
554 *Metabolism*. 2017:271678X16686093.

- 555 9. Bailey DM, Rasmussen P, Evans KA, Bohm AM, Zaar M, Nielsen HB, Brassard P,
556 Nordsborg NB, Homann PH, Raven PB, McEneny J, Young IS, McCord JM and Secher NH.
557 Hypoxia compounds exercise-induced free radical formation in humans; partitioning
558 contributions from the cerebral and femoral circulation. *Free Radical Biology & Medicine*
559 . 2018;124:104-113.
- 560 10. Vuilleumier JP and Keck E. Fluorimetric assay of vitamin C in biological materials using
561 a centrifugal analyser with fluorescence attachment. *Journal of Micronutritional Analysis*.
562 1993;5:25-34.
- 563 11. Catignani GL and Bieri JG. Simultaneous determination of retinol and alpha-
564 tocopherol in serum or plasma by liquid chromatography. *Clinical Chemistry*. 1983;29:708-
565 712.
- 566 12. Thurnham DI, Smith E and Flora PS. Concurrent liquid-chromatographic assay of
567 retinol, α -tocopherol, β -carotene, α -carotene, lycopene, and β -cryptoxanthin in plasma, with
568 tocopherol acetate as internal standard. *Clinical Chemistry*. 1988;34:377-381.
- 569 13. Bailey DM, Rasmussen P, Overgaard M, Evans KA, Bohm AM, Seifert T, Brassard P,
570 Zaar M, Nielsen HB, Raven PB and Secher NH. Nitrite and S-Nitrosohemoglobin exchange
571 across the human cerebral and femoral circulation: relationship to basal and exercise blood
572 flow responses to hypoxia. *Circulation*. 2017;135:166-176.
- 573 14. Rogers SC, Khalatbari A, Gapper PW, Frenneaux MP and James PE. Detection of
574 human red blood cell-bound nitric oxide. *Journal of Biological Chemistry*. 2005;280:26720-
575 26728.
- 576 15. Pinder AG, Rogers SC, Khalatbari A, Ingram TE and James PE. The measurement of
577 nitric oxide and its metabolites in biological samples by ozone-based chemiluminescence.
578 *Methods in molecular biology*. 2009;476:10-27.

- 579 16. Wesseling KH, Jansen JR, Settels JJ and Schreuder JJ. Computation of aortic flow from
580 pressure in humans using a nonlinear, three-element model. *Journal of applied physiology*.
581 1993;74:2566-73.
- 582 17. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB,
583 Beilin LJ, Burke V, Mori TA and Green D. Improved analysis of brachial artery ultrasound using
584 a novel edge-detection software system. *Journal of applied physiology*. 2001;91:929-37.
- 585 18. Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J,
586 Lewis NC, Day TA and Ainslie PN. Regional brain blood flow in man during acute changes in
587 arterial blood gases. *Journal of Physiology*. 2012;590:3261-75.
- 588 19. Hoiland RL, Ainslie PN, Bain AR, MacLeod DB, Stenbridge M, Drvis I, Madden D, Barak
589 O, MacLeod DM and Dujic Z. Beta1-Blockade increases maximal apnea duration in elite
590 breath-hold divers. *Journal of applied physiology*. 2017;122:899-906.
- 591 20. Willie CK, Ainslie PN, Drvis I, MacLeod DB, Bain AR, Madden D, Maslov PZ and Dujic Z.
592 Regulation of brain blood flow and oxygen delivery in elite breath-hold divers. *Journal of*
593 *Cerebral Blood Flow and Metabolism*. 2015;35:66-73.
- 594 21. Myerson A and Loman J. Internal jugular venous pressure in man: Its relationship to
595 cerebrospinal fluid and carotid arterial pressures. *Archives of Neurology and Psychiatry*.
596 1932;27:836-846.
- 597 22. Bailey DM, Willie CK, Hoiland RL, Bain AR, MacLeod DB, Santoro MA, DeMasi DK,
598 Andrijanic A, Mijacika T, Barak OF, Dujic Z and Ainslie PN. Surviving without oxygen: how low
599 can the human brain go? *High altitude medicine & biology*. 2017;18:73-79.
- 600 23. Fall L, Brugniaux JV, Davis D, Marley CJ, Davies B, New KJ, McEneny J, Young IS and
601 Bailey DM. Redox-regulation of haemostasis in hypoxic exercising humans: a randomised

- 602 double-blind placebo-controlled antioxidant study. *The Journal of physiology*. 2018;596:4879-
603 4891.
- 604 24. Bain AR, Ainslie PN, Hoiland RL, Barak OF, Drvis I, Stembridge M, MacLeod DM,
605 McEneny J, Stacey BS, Tuailon E, Marchi N, De Maudave AF, Dujic Z, MacLeod DB and Bailey
606 DM. Competitive apnea and its effect on the human brain: focus on the redox regulation of
607 blood-brain barrier permeability and neuronal-parenchymal integrity. *FASEB journal : official
608 publication of the Federation of American Societies for Experimental Biology*. 2018;32:2305-
609 2314.
- 610 25. Turrens JF. Mitochondrial formation of reactive oxygen species. *Journal of Physiology*.
611 2003;552.2:335-344.
- 612 26. Murphy MP. How mitochondria produce reactive oxygen species. *The Biochemical
613 journal*. 2009;417:1-13.
- 614 27. Augusto O and Truzzi DR. Carbon dioxide redox metabolites in oxidative eustress and
615 oxidative distress. *Biophys Rev*. 2021;13:889-891.
- 616 28. Bailey DM, Taudorf S, Berg RMG, Lundby C, McEneny J, Young IS, Evans KA, James PE,
617 Shore A, Hullin DA, McCord JM, Pedersen BK and Moller K. Increased cerebral output of free
618 radicals during hypoxia: implications for acute mountain sickness? *American Journal of
619 Physiology (Regulatory, Integrative and Comparative Physiology)*. 2009;297:R1283-1292.
- 620 29. Bailey DM. Oxygen and brain death; back from the brink. *Experimental physiology*.
621 2019;104:1769-1779.
- 622 30. Bailey DM, Young IS, McEneny J, Lawrenson L, Kim J, Barden J and Richardson RS.
623 Regulation of free radical outflow from an isolated muscle bed in exercising humans.
624 *American Journal of Physiology (Heart and Circulatory Physiology)*. 2004;287:H1689-H1699.

- 625 31. Janigro D, Bailey DM, Lehmann S, Badaut J, O’Flynn R, Hirtz C and Marchi N.
626 Peripheral blood and salivary biomarkers of blood–brain barrier permeability and neuronal
627 damage: clinical and applied concepts. *Frontiers in Neurology*. 2021.
- 628 32. Jia L, Bonaventura C, Bonaventura J and Stamler JS. S-nitrosohaemoglobin: a dynamic
629 activity of blood involved in vascular control. *Nature*. 1996;380:221-6.
- 630 33. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw
631 MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO and
632 Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human
633 circulation. *Nature Medicine*. 2003;9:1498-505.
- 634 34. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM. Activation of
635 nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature*.
636 1999;399:601-5.
- 637 35. O’Gallagher K, Rosentreter RE, Elaine Soriano J, Roomi A, Saleem S, Lam T, Roy R,
638 Gordon GR, Raj SR, Chowienczyk PJ, Shah AM and Phillips AA. The Effect of a Neuronal Nitric
639 Oxide Synthase Inhibitor on Neurovascular Regulation in Humans. *Circ Res*. 2022;131:952-
640 961.
- 641 36. Gladwin MT, Shelhamer JH, Schechter AN, Pease-Fye ME, Waclawiw MA, Panza JA,
642 Ognibene FP and Cannon RO, III. Role of circulating nitrite and S-nitrosohemoglobin in the
643 regulation of regional blood flow in humans. *Proceedings of the National Academy of Sciences
644 of the United States of America*. 2000;97:11482-11487.
- 645 37. Stamler J, Jia L, Eu J, McMahon T, Demchenko I, Bonaventura J, Gernet K and
646 Piantadosi C. Blood Flow Regulation by S-Nitrosohemoglobin in the Physiological Oxygen
647 Gradient. *Science*. 1997;276:2034-2037.

- 648 38. Pawloski JR, Hess DT and Stamler JS. Export by red blood cells of nitric oxide
649 bioactivity. *Nature*. 2001;409:622-6.
- 650 39. Ladurner A, Schmitt CA, Schachner D, Atanasov AG, Werner ER, Dirsch VM and Heiss
651 EH. Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid
652 modulation of its phosphorylation status. *Free radical biology & medicine*. 2012;52:2082-90.
- 653 40. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, Gow AJ,
654 Pawloski JR, Watke P, Singel DJ, Piantadosi CA and Stamler JS. Nitric oxide in the human
655 respiratory cycle. *Nature Medicine*. 2002;8:711-7.
- 656 41. Gladwin MT, Wang X, Reiter CD, Yang BK, Vivas EX, Bonaventura C and Schechter AN.
657 S-Nitrosohemoglobin is unstable in the reductive erythrocyte environment and lacks O₂/NO-
658 linked allosteric function. *The Journal of biological chemistry*. 2002;277:27818-28.
- 659 42. Wang X, Bryan NS, MacArthur PH, Rodriguez J, Gladwin MT and Feelisch M.
660 Measurement of nitric oxide levels in the red cell: validation of tri-iodide-based
661 chemiluminescence with acid-sulfanilamide pretreatment. *The Journal of biological*
662 *chemistry*. 2006;281:26994-7002.
- 663 43. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C,
664 Hogg N, Schechter AN and Gladwin MT. Enzymatic function of hemoglobin as a nitrite
665 reductase that produces NO under allosteric control. *Journal of Clinical Investigation*.
666 2005;115:2099-107.
- 667 44. Guzy R, Hoyos B, Robin E, Chen H, Liu L, Mansfield K, Simon M, Hammerling U and
668 Schumacker P. Mitochondrial complex III is required for hypoxia-induced ROS production and
669 cellular oxygen sensing. *Cell Metabolism*. 2005;1:401-8.
- 670 45. Williams NH and Yandell JK. Outer-sphere electron-transfer reactions of ascorbic
671 anions. *Australian Journal of Chemistry*. 1982;35:1133-1144.

672 46. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, a-
673 tocopherol, and ascorbate. *Archives of Biochemistry and Biophysics*. 1993;300:535-543.

674

675 LEGENDS

676 Figure 1. Experimental hypotheses (A) and design (B)

677 A. Predicted differential disruption of cerebral redox homeostasis and implications for
678 cerebral bioenergetic function in response to pathological extremes of oxygen (O₂) and
679 carbon dioxide (CO₂) during hypoxemic hypercapnia (HHA, prior normoxic normoventilation)
680 and isolated hyperoxemic hypercapnia (IHA, prior hyperoxic hyperventilation) apneas. O₂/CO₂
681 sensing by the red blood cell (RBC) and mitochondrion is allosterically coupled to formation
682 of nitric oxide (NO[•])⁴³ and reactive oxygen/nitrogen (ROS/RNS)⁴⁴ species that titrate (global)
683 cerebral blood flow (gCBF) coupling substrate (O₂ and glucose) delivery to demand. The more
684 marked reduction in arterial partial pressure of oxygen (PO₂) during the HHA trial is
685 hypothesized to induce a more pronounced elevation in cerebral oxidative-nitrosative stress
686 (OXNOS) reflected by a free radical-mediated reduction in vascular NO bioavailability
687 (manifest as increased net cerebral output of free radicals and lipid peroxidants and
688 corresponding lower net cerebral uptake of nitrite (NO₂⁻) or S-nitrosohemoglobin (SNO-Hb)
689 leading to a suppression of cerebral hypoxic vasodilation relative to IHA trial. Note typical
690 human experimental setup highlighting arterial-jugular venous (transcerebral) sampling of
691 blood combined with volumetric assessment of gCBF. R[•], free radical; NO₂⁻, nitrite; N₂O₃,
692 nitrogen tri-oxide; ONOO⁻, peroxyxynitrite (not measured); PaO₂, arterial partial pressure of
693 oxygen; PaCO₂, arterial partial pressure of carbon dioxide; a-jv_D, arterio-jugular venous
694 concentration difference; SNA, sympathetic nervous activity (not measured). B. Two

695 submaximal (practice) apneas preceded separate trials involving prior normoxic (21 % O₂)
696 normoventilation resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the
697 second followed prior hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia
698 resulting in isolated hypercapnic apnea (IHA). The first practice apnea was performed at
699 functional residual capacity (FRC) for 6 involuntary body movements (IBMs) and the second
700 practice at total lung capacity (TLC) for 10 IBMs. Both maximal apneas were performed at
701 TLC. Measurements were performed at baseline and timed to coincide with the end of each
702 maximal apnea.

703

704 **Figure 2. Transcerebral exchange of oxidative stress biomarkers**

705 Values are mean ± SD; Separate trials involving prior normoxic (21 % O₂) normoventilation
706 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior
707 hyperoxic (100 % O₂) hyperventilation, designed to prevent hypoxemia resulting in isolated
708 hypercapnic apnea (IHA); Circles and triangles denote individual data points for participants
709 during the NX and HX trials respectively; Total lipid soluble antioxidants (LSA) calculated as the
710 cumulative concentration of α/γ -tocopherol, α/β -carotene, retinol and lycopene; A^{•-},
711 ascorbate free radical; LOOH, lipid hydroperoxides. Exchange calculated as the product of
712 global cerebral plasma/serum flow and arterio-jugular venous concentration difference.
713 Positive or negative gradients reflect net cerebral uptake (loss or consumption) or output
714 (gain or formation) respectively. Since the concentration of ascorbate in human plasma is
715 orders of magnitude greater than any oxidizing free radical combined with the low one-
716 electron reduction potential for the A^{•-}/ascorbate monanion (AH⁻) couple ($E^{\circ'} = 282 \text{ mV}$)⁴⁵,
717 any oxidizing species (R[•]) generated locally within the cerebral circulation will result in the
718 one-electron oxidation of ascorbate to form the distinctive EPR-detectable A^{•-} doublet (R[•] +

719 $AH^- \rightarrow A^{\bullet-} + R-H$, Panel D inset with main coupling hydrogen highlighted in red)⁴⁶. *different
720 between state for given trial ($P < 0.05$); †different between trial for given state ($P < 0.05$).

721

722

723

724 **Figure 3. Local distribution of nitric oxide (NO) metabolites**

725 Values are mean \pm SD; Separate trials involving prior normoxic (21 % O₂) normoventilation
726 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior
727 hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia resulting in isolated
728 hypercapnic apnea (IHA); NO, nitric oxide; NO₂⁻, nitrite; RSNO, S-nitrosothiols; SNO-Hb, S-
729 nitrosohemoglobin; HbNO, nitrosylhemoglobin; A, arterial; V, venous. Plasma NO₂⁻: Trial ($P =$
730 0.010); State ($P = 0.003$); Site ($P = <0.001$); Trial \times Site ($P = 0.048$); RBC NO₂⁻: Trial ($P = 0.048$);
731 Site ($P = 0.047$); SNO-Hb: Trial ($P = 0.014$); State ($P = 0.036$); Site ($P = 0.019$); Trial \times State ($P =$
732 0.022); HbNO: Trial ($P = 0.002$); Site ($P = <0.001$); Trial \times State ($P = 0.024$); Trial \times State \times Site
733 ($P = 0.045$); Total plasma NO: Trial ($P = 0.009$); State ($P = 0.033$); Site ($P = <0.001$); Trial \times Site
734 ($P = 0.042$); Total RBC NO: State ($P = 0.042$); Total plasma + RBC NO: Trial ($P = 0.044$); Site ($P =$
735 0.036). *different between state for given trial ($P < 0.05$); †different between trial for given
736 state ($P < 0.05$).

737

738 **Figure 4. Transcerebral exchange of nitrosative stress biomarkers**

739 Values are mean \pm SD; Separate trials involving prior normoxic (21 % O₂) normoventilation
740 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior
741 hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia resulting in isolated

742 hypercapnic apnea (IHA); Circles and triangles denote individual data points for participants
743 during the NX and HX trials respectively; NO, nitric oxide; NO₂⁻, nitrite; RSNO, S-nitrosothiols;
744 SNO-Hb, S-nitrosohemoglobin; HbNO, nitrosylhemoglobin. Exchange calculated as the
745 product of global cerebral plasma (A-C) or red blood cell (RBC, D-G) or whole blood (H) flow
746 and arterio-jugular venous concentration difference. Positive or negative gradients reflect net
747 cerebral uptake (loss or consumption) or output (gain or formation) respectively. Note typical
748 smoothed traces for arterial concentration of metabolites obtained by ozone-based
749 chemiluminescence (same scale). *different between state for given trial ($P < 0.05$); †different
750 between trial for given state ($P < 0.05$).

751 **SUPPLEMENTAL MATERIAL**

752 **Supplemental Table 1. Blood gas variables**

753 Values are mean \pm SD; PO₂/PCO₂, partial pressure of oxygen/carbon dioxide; SO₂,
754 oxyhemoglobin saturation; cO₂, oxygen content; H⁺, hydrogen ions HCO₃⁻, bicarbonate ions;
755 Hb, hemoglobin; Hct, hematocrit. *different between state for given trial and site ($P < 0.05$);
756 †different between trial for given state and site ($P < 0.05$).

757

758 **Supplemental Table 2. Cardiopulmonary function**

759 Values are mean \pm SD; HR, heart rate; SV, stroke volume; \dot{Q} , cardiac output; MAP, mean
760 arterial pressure; IJVP, internal jugular venous pressure; CPP, cerebral perfusion pressure. Δ ,
761 apnea minus eupnea; *different between state for given trial ($P < 0.05$); †different between
762 trial for given state or Δ ($P < 0.05$).

763

764 **Supplemental Table 3. Cerebral bioenergetic function**

765 Values are mean \pm SD; \dot{Q}_{ICA} , internal carotid artery flow; \dot{Q}_{VA} , vertebral artery flow; gCBF,
766 global cerebral blood flow; gCDO₂, global cerebral delivery of oxygen; gCD_{Glucose}, global
767 cerebral delivery of glucose; CMR, cerebral metabolic rate; Δ , apnea minus eupnea.
768 *different between state for given trial ($P < 0.05$); †different between trial for given state ($P <$
769 0.05).

770

771 **Table 1. Oxidative stress**

772 Values are mean \pm SD; a-v_D, arterio-jugular venous concentration difference; Total lipid
773 soluble antioxidants (LSA) calculated as the cumulative concentration of α/γ -tocopherol, α/β -
774 carotene, retinol and lycopene; A⁻, ascorbate free radical; LOOH, lipid hydroperoxides.

775 Positive or negative $a-v_D$ reflects cerebral uptake (loss or consumption) or output (gain or
776 formation) respectively.

777

778 **Table 2. Nitrosative stress**

779 Values are mean \pm SD; $a-v_D$, ; NO, nitric oxide; NO_2^- , nitrite; RSNO, S-nitrosothiols; SNO-Hb, S-
780 nitrosohemoglobin; HbNO, nitrosylhemoglobin. Positive or negative $a-v_D$ reflects cerebral
781 uptake (loss or consumption) or output (gain or formation) respectively. *different between
782 site for given trial and state ($P < 0.05$); †different between trial for given state and site ($P <$
783 0.05).

784 **ACKNOWLEDGMENTS**

785 The authors acknowledge the cheerful cooperation of all participants. We are also indebted
786 to Professor IS Young and Dr Jane McEneny for specialist technical input.

787

788 **SOURCES OF FUNDING**

789 This study was funded by a Royal Society Wolfson Research Fellowship (#WM170007) and
790 Higher Education Funding Council for Wales (Dr Bailey), Canada Research Chair (CRC) and
791 Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery grant (Dr
792 Ainslie), NSERC (Drs Bain and Hoiland), Autonomic Province of Vojvodina, Serbia (#142-451-
793 2541, Dr Barak) and Croatian Science Foundation Grant (#IP-2014-09-1937, Drs Barak, Drvis
794 and Ainslie).

795

796 **DISCLOSURES**

797 Dr Bailey is Editor-in-Chief of Experimental Physiology, Chair of the Life Sciences Working
798 Group, member of the Human Spaceflight and Exploration Science Advisory Committee to
799 the European Space Agency, member of the Space Exploration Advisory Committee to the UK
800 Space Agency, member of the National Cardiovascular Network for Wales and South East
801 Wales Vascular Network and is affiliated to the companies FloTBI, Inc. and Bexorg, Inc.
802 focused on the technological development of novel biomarkers of brain injury in humans.

Supplemental Table 1. Blood gas variables

Trial: State: Site:	Hypoxemic Hypercapnia Apnea (n = 10)				Isolated Hypercapnic Apnea (n = 10)			
	Eupnea		Apnea		Eupnea		Apnea	
	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous
PO ₂ (mmHg)	97 ± 12	34 ± 4	36 ± 5*	28 ± 5*	589 ± 23†	28 ± 10	425 ± 79*†	80 ± 9*†
Trial (P = <0.001); State (P = <0.001); Site (P = <0.001); Trial × Site (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = <0.001)								
SO ₂ (%)	98 ± 1	58 ± 7	60 ± 11*	40 ± 11*	100 ± 0†	51 ± 19	100 ± 0*†	93 ± 2*†
Trial (P = <0.001); Site (P = <0.001); Trial × State (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = 0.008)								
cO ₂ (mL/dL)	18.3 ± 1.7	10.7 ± 1.6	11.7 ± 2.4*	8.0 ± 2.6*	20.6 ± 2.0†	9.7 ± 3.6	20.0 ± 1.6*†	17.8 ± 1.9*†
Trial (P = <0.001); Site (P = <0.001); Trial × State (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = 0.006)								
PCO ₂ (mmHg)	36 ± 5	47 ± 5	51 ± 3*	54 ± 4*	16 ± 4†	31 ± 6†	58 ± 5*†	59 ± 15*
Trial (P = 0.006); State (P = <0.001); Site (P = <0.001); Trial × State (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = 0.033)								
pH (units)	7.440 ± 0.043	7.384 ± 0.032	7.360 ± 0.023*	7.348 ± 0.021*	7.700 ± 0.078†	7.542 ± 0.071†	7.283 ± 0.043*†	7.306 ± 0.154*
Trial (P = 0.005); State (P = <0.001); Site (P = 0.001); Trial × State (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = 0.008)								
H ⁺ (μM)	36 ± 3	41 ± 3	44 ± 2	45 ± 2	20 ± 4	29 ± 4	52 ± 5	52 ± 12
Trial (P = 0.041); State (P = <0.001); Site (P = 0.001); Trial × State (P = <0.001); State × Site (P = <0.001); Trial × State (P = <0.001)								
HCO ₃ ⁻ (mM)	24.2 ± 2.5	27.9 ± 2.3	27.9 ± 3.1*	29.8 ± 2.0*	19.8 ± 2.0†	26.0 ± 2.2†	27.2 ± 1.9*	27.9 ± 2.1*†
Trial (P = 0.001); State (P = <0.001); Site (P = <0.001); Trial × State (P = 0.002); State × Site (P = <0.001); Trial × State × Site (P = <0.001)								
Hb (g/dL)	13.7 ± 1.4	13.7 ± 1.4	14.3 ± 1.2	14.5 ± 1.0	14.0 ± 1.4	14.2 ± 1.5	14.0 ± 1.2	14.1 ± 1.4
Trial × State (P = 0.034)								
Hct (%)	42 ± 4	42 ± 4	44 ± 4	44 ± 3	43 ± 4	44 ± 5	43 ± 4	43 ± 4
Trial × State (P = 0.023)								

Supplemental Table 2. Cardiopulmonary function

Trial: State:	Hypoxemic Hypercapnia Apnea (n = 10)			Isolated Hypercapnic Apnea (n = 10)		
	Eupnea	Apnea	Δ	Eupnea	Apnea	Δ
HR (b/min)	64 ± 7	59 ± 14	-5 ± 12	65 ± 11	69 ± 13	4 ± 18
SV (mL/min)	78 ± 16	67 ± 16*	-11 ± 15	86 ± 17 [†]	90 ± 17 [†]	5 ± 12 [†]
<i>Trial (P = 0.001); Trial × State (P = 0.001)</i>						
Q̇ (L/min)	4.92 ± 0.91	3.91 ± 1.17*	-1.01 ± 1.21	5.46 ± 1.01	6.29 ± 1.97 [†]	0.83 ± 1.73 [†]
<i>Trial (P = 0.001); Trial × State (P = 0.029)</i>						
MAP (mmHg)	116 ± 8	177 ± 8*	61 ± 9	111 ± 8 [†]	158 ± 16* [†]	47 ± 14* [†]
<i>Trial (P = 0.001); State (P = <0.001); Trial × State (P = 0.018)</i>						
IJVP (mmHg)	10 ± 2	22 ± 1*	12 ± 2	10 ± 2	17 ± 5* [†]	7 ± 5* [†]
<i>Trial (P = 0.015); State (P = <0.001); Trial × State (P = 0.016)</i>						
CPP (mmHg)	106 ± 9	155 ± 7	49 ± 8	101 ± 9	141 ± 16	40 ± 13
<i>Trial (P = 0.002); State (P = <0.001); Trial × State (P = 0.112)</i>						

Supplemental Table 3. Cerebral bioenergetic function

Trial: State:	Hypoxemic Hypercapnia Apnea (n = 10)			Isolated Hypercapnic Apnea (n = 10)		
	Eupnea	Apnea	Δ	Eupnea	Apnea	Δ
<i>Perfusion</i>						
\dot{Q}_{ICA} (mL/min)	458 ± 55	848 ± 148*	390 ± 119	317 ± 92†	938 ± 211*	621 ± 174†
State (P = <0.001); Trial × State (P = 0.001)						
\dot{Q}_{VA} (mL/min)	177 ± 82	307 ± 133*	130 ± 54	113 ± 55†	357 ± 198*	244 ± 146†
State (P = <0.001); Trial × State (P = 0.009)						
gCBF (mL/min)	635 ± 84	1155 ± 147*	520 ± 114	31 ± 7†	92 ± 22*	865 ± 260†
State (P = <0.001); Trial × State (P = 0.002)						
<i>Metabolism</i>						
gCDO ₂ (mL/min)	116 ± 22	137 ± 43*	20 ± 30	88 ± 20†	259 ± 63*†	171 ± 52†
Trial (P = <0.001); State (P = <0.001); Trial × State (P = <0.001)						
gCD _{Gluc} (mM/min)	3.45 ± 0.60	6.30 ± 1.07*	2.85 ± 0.77	2.20 ± 0.49†	7.48 ± 1.57*†	5.28 ± 1.40†
State (P = <0.001); Trial × State (P = <0.001)						
gCMRO ₂ (mL/min)	47 ± 8	43 ± 12	-5 ± 17	48 ± 19	28 ± 8	-19 ± 18
State (P = 0.015)						
gCMR _{Glucose} (mM/min)	0.37 ± 0.09	0.30 ± 0.09	-0.07 ± 0.14	0.47 ± 0.14	0.50 ± 0.52	0.04 ± 0.58
Trial (P = 0.044)						

Table 1. Oxidative stress

Trial: State: Site:	Hypoxemic Hypercapnia Apnea (n = 10)				Isolated Hypercapnic Apnea (n = 10)			
	Eupnea		Apnea		Eupnea		Apnea	
	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous
<i>Antioxidants</i>								
Ascorbate (μM)	59.3 \pm 11.0	59.2 \pm 10.0	61.8 \pm 8.9	53.5 \pm 6.4	61.0 \pm 6.7	60.5 \pm 5.3	63.0 \pm 5.6	60.0 \pm 3.7
Site ($P = 0.007$); Trial \times Site ($P = 0.017$); State \times Site ($P = 0.015$)								
a-v _D (μM)	0.2 \pm 4.3		8.3 \pm 5.6		0.5 \pm 4.9		3.0 \pm 4.0	
Trial ($P = 0.017$); State ($P = 0.015$)								
α -tocopherol (μM)	22.1 \pm 3.9	21.7 \pm 3.2	24.4 \pm 3.0	20.4 \pm 3.4	22.5 \pm 4.9	22.7 \pm 4.1	22.7 \pm 2.9	21.3 \pm 3.2
Site ($P = 0.008$); State \times Site ($P = 0.011$)								
a-v _D (μM)	0.3 \pm 1.5		4.0 \pm 2.6		-0.1 \pm 4.2		1.4 \pm 2.6	
State ($P = 0.010$)								
Total LSA (μM)	25.6 \pm 3.6	25.2 \pm 3.1	28.0 \pm 2.6	23.7 \pm 3.0	26.0 \pm 4.7	26.2 \pm 3.9	26.0 \pm 2.5	24.4 \pm 2.7
Site ($P = 0.006$); State \times Site ($P = 0.010$)								
a-v _D (μM)	0.4 \pm 2.1		4.3 \pm 2.4		-0.1 \pm 4.7		1.6 \pm 2.6	
State ($P = 0.011$)								
<i>Free radicals</i>								
A [•] ($\text{AU} \times 10^2$)	320 \pm 107	313 \pm 98	344 \pm 95	473 \pm 127	322 \pm 70	333 \pm 102	363 \pm 143	386 \pm 129
State ($P = 0.009$); Site ($P = 0.046$); State \times Site ($P = 0.048$)								
a-v _D ($\text{AU} \times 10^2$)	6 \pm 130		-129 \pm 96		-12 \pm 143		-24 \pm 91	
State ($P = 0.048$)								
<i>Lipid peroxidation</i>								
LOOH (μM)	1.15 \pm 0.17	1.16 \pm 0.13	1.22 \pm 0.25	1.74 \pm 1.20	1.19 \pm 0.15	1.25 \pm 0.22	1.27 \pm 0.18	1.45 \pm 0.24
State ($P = 0.038$); Site ($P = 0.045$); State \times Site ($P = 0.048$)								
a-v _D (μM)	-0.01 \pm 0.14		-0.52 \pm 0.97		-0.07 \pm 0.23		-0.18 \pm 0.15	
State ($P = 0.047$)								

Table 2. Nitrosative stress

Trial: State: Site:	Hypoxemic Hypercapnia Apnea (n = 10)				Isolated Hypercapnic Apnea (n = 10)			
	Eupnea		Apnea		Eupnea		Apnea	
	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous
<i>Plasma</i>								
NO₂⁻ (nM)	161 ± 45	149 ± 35	124 ± 45	85 ± 34	210 ± 80	154 ± 42	176 ± 55	108 ± 45
<i>Trial (P = 0.010); State (P = 0.003); Site (P = <0.001); Trial × Site (P = 0.048)</i>								
a-v _D (nM)	12 ± 48		39 ± 46		55 ± 55		68 ± 34	
<i>Trial (P = 0.048)</i>								
RSNO (nM)	9 ± 9	7 ± 8	8 ± 11	6 ± 9	6 ± 5	4 ± 4	5 ± 6	5 ± 2
a-v _D (nM)	2 ± 6		2 ± 4		1 ± 3		1 ± 4	
Total NO (nM)	170 ± 43	155 ± 37	132 ± 52	91 ± 39	215 ± 82	159 ± 45	181 ± 58	113 ± 47
<i>Trial (P = 0.009); State (P = 0.033); Site (P = <0.001); Trial × Site (P = 0.042)</i>								
a-v _D (nM)	14 ± 46		41 ± 46		57 ± 55		68 ± 37	
<i>Trial (P = 0.042)</i>								
<i>Red blood cell</i>								
NO₂⁻ (nM)	171 ± 62	138 ± 39	190 ± 71	158 ± 52	216 ± 84	174 ± 65	202 ± 72	210 ± 96
<i>Trial (P = 0.048); Site (P = 0.047)</i>								
a-v _D (nM)	33 ± 64		33 ± 94		42 ± 106		-8 ± 128	
SNO-Hb (nM)	10 ± 3	15 ± 5	16 ± 5	32 ± 30	9 ± 4	14 ± 6	9 ± 3	12 ± 3
<i>Trial (P = 0.014); State (P = 0.036); Site (P = 0.019); Trial × State (P = 0.022)</i>								
a-v _D (nM)	-5 ± 5		-16 ± 31		-5 ± 6		-3 ± 5	
HbNO (nM)	21 ± 5	41 ± 15*	32 ± 20	66 ± 38*	7 ± 3†	30 ± 16*	11 ± 8†	24 ± 17†
<i>Trial (P = 0.002); Site (P = <0.001); Trial × State (P = 0.024); Trial × State × Site (P = 0.045)</i>								
a-v _D (nM)	-20 ± 16		-34 ± 31		-1 ± 13		-29 ± 33†	
<i>Trial × State (P = 0.049)</i>								
Total NO (nM)	202 ± 62	194 ± 47	239 ± 81	256 ± 81	232 ± 81	218 ± 65	222 ± 72	245 ± 103
<i>State (P = 0.042)</i>								
a-v _D (nM)	8 ± 68		-17 ± 120		14 ± 112		-24 ± 139	
<i>Plasma + Red blood cell</i>								
Total NO (nM)	371 ± 69	349 ± 50	371 ± 103	347 ± 107	447 ± 96	376 ± 93	403 ± 88	358 ± 134
<i>Trial (P = 0.044); Site (P = 0.036)</i>								
a-v _D (nM)	22 ± 68		24 ± 140		71 ± 85		44 ± 161	





Figure 1. Experimental hypotheses (A) and design (B)




Figure 2. Transcerebral exchange of oxidative stress biomarkers




Figure 3. Local distribution of nitric oxide (NO) metabolites




Figure 4. Transcerebral exchange of nitrosative stress biomarkers